drug
(brimonidine tartrate + carbachol)
Marketedupdated 6mo agoby Tenpoint Therapeutics Ltd
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 6all catalysts(0)
nothing on the calendar yet
Patent cliff
source: FDA Orange Bookfirst barrier falls
Jan 28, 2029
~2.2 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (2)
- Nov 10, 2042formulationUS 12268662
- May 24, 2030method-of-use (U-4420)US 84554943.6y
FDA exclusivities (1)
- Jan 28, 2029NPNP2.2y
News(2)
- Growth mode: 3 biotechs that are staffing up after series B raisesBiotechs that announced series B financing this year and are expanding their workforces include one that raised $2.1 billion and has partnerships with Eli Lilly, Johnson & Johnson and Novartis.biospace · 1mo ago
- Fierce Biotech Fundraising Tracker '26: Nouscom nabs $135M series D; Estuary channels $93M series AThe Fierce Biotech Fundraising Tracker records venture capital rounds of $50 million or more secured by biotechs.fiercebiotech · 10mo ago
Data sources
last refreshed 3h ago
Found something off?
comments(0)
5-min edit window · permanent after that